C-type lectin receptor (on dendritic cell) (CLR (on DC) or DC-CLR)
Target
CLR (on DC) or DC-CLR
Molecular classification
Receptor, Pattern recognition receptor (PRR), Lectin, C-type lectin-like receptor (CLR or CTLR), Some also classified as "immunoreceptor" or "cell surface glycoprotein"
01
Overview
C-type lectin receptors (CLRs) on dendritic cells are a diverse family of calcium-dependent carbohydrate-binding proteins that function predominantly as pattern recognition receptors, recognizing pathogen- and damage-associated glycans and self-antigens. They mediate key innate and adaptive immune activities by capturing and presenting antigens, modulating cytokine profiles, polarizing T cell responses, and participating in immunological tolerance or activation. Individual CLRs on dendritic cells—such as DC-SIGN, Dectin-1, Dectin-2, CLEC9A, and DCIR—play distinct and sometimes overlapping roles in immunity, pathogen recognition, vaccination, and disease processes, with their expression and function finely regulated by maturation and environmental stimuli
Antigen targeting: Use of glycosylated antigens or antibody–antigen conjugates to direct delivery and presentation by dendritic cells via these receptors. Immune modulation: Modulation of downstream signaling, cytokine production, and T cell polarization through receptor engagement (e.g., via ITAM/hemITAM or ITIM signaling pathways, crosstalk with TLRs or other PRRs)
03
Biological functions
Immune responseAntigen recognition and uptakeAntigen presentationModulation of T cell polarizationSignal transductionRegulation of cytokine productionPathogen recognitionCrosstalk with other PRRs (e.g., Toll-like receptor)Induction of tolerance or immunity depending on ligand/context
04
Disease associations
Infection (bacterial, viral, fungal, parasitic)InflammationCancer (tumor immune modulation and recognition of tumor glycans)Allergic/atopic diseaseAutoimmune diseaseOther immune system–related disorders
05
Safety considerations
Potential for inappropriate immune activation or tolerance (e.g., unwanted immunosuppression or exacerbated inflammation/allergy depending on ligand and context)Risk of impaired pathogen clearance or tolerance induction in targeting strategiesPossibility of autoimmunity if tolerance mechanisms are dysregulated
06
Interacting drugs
No approved drugs directly targeting DC-CLRs, but multiple vaccine/adjuvant strategies actively target or utilize these receptors for antigen delivery and immunomodulation.
1 more in the full profile.
07
Biomarkers
Expression of CLR subtypes (e.g., DC-SIGN, Dectin-1, Dectin-2, CLEC9A) can be used as dendritic cell subset markers.Tumor-associated glycans (e.g., Lewis antigens, GalNAc) detected by certain CLRs in cancer immunoprofiling.CLR expression profiling in inflammation, infection, or allergy for stratifying immune responses
Beyond the preview
Go deeper on C-type lectin receptor (on dendritic cell) (CLR (on DC) or DC-CLR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-type lectin receptor (on dendritic cell) (CLR (on DC) or DC-CLR).